Pan‐cancer analysis of altered glycosyltransferases confers poor clinical outcomes
Clinical and Translational Discovery · 2022
DOI: 10.1002/ctd2.100 ↗At a glance
Journal article in Clinical and Translational Discovery, 2022. Written by Saravanakumar Marimuthu and 2 co-authors. Institution: Department of Biochemistry and Molecular Biology, College of Medicine, University of Nebraska Medical Center, Omaha, NE, USA. Cited 3 times so far (Crossref); 10 references. The full text is freely available (open access, CC BY 4.0). Funded by: NCI NIH HHS, U.S. Department of Health and Human Services, National Institutes of Health.
Abstract (original language)
Glycosylation is a post-translational modification (PTM) process that attaches carbohydrates to proteins and lipids.Protein glycosylation can be N-linked or O-linked depending on adding sugars onto the side chains of Asn or Ser/Thr residues, respectively.PTM comprises glycanmodifying enzymes glycosyltransferases (GTs) and glycosidases.O-glycan truncation, N-glycan branching, sialylation and fucosylation are the most well-known cancerassociated glycosylations.The glycan-modifying enzymes stimulate various malignant behaviours of tumours, such as tumour proliferation, invasion, epithelial-mesenchymal transition, metastasis, angiogenesis, immune modulation and cell-matrix interactions.1,2 Over 200 GTs regulate glycosylation.An unbiased global approach must be used to identify glycogenes in cancer.In this study,
Subjects
Author keywords
Authors and institutions
- Department of Biochemistry and Molecular Biology, College of Medicine, University of Nebraska Medical Center, Omaha, NE, USA.
- Eppley Institute for Research in Cancer and Allied Diseases, Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE, USA.
- Department of Pathology and Microbiology, College of Medicine, University of Nebraska Medical Center, Omaha, NE, USA.
Funding
- NCI NIH HHS
- U.S. Department of Health and Human Services
- National Institutes of Health
- National Cancer Institute
Cite
APA
Marimuthu, S., Batra, S. K., & Ponnusamy, M. P. (2022). Pan‐cancer analysis of altered glycosyltransferases confers poor clinical outcomes. Clinical and Translational Discovery. https://doi.org/10.1002/ctd2.100
Vancouver
Marimuthu S, Batra SK, Ponnusamy MP. Pan‐cancer analysis of altered glycosyltransferases confers poor clinical outcomes. Clinical and Translational Discovery. 2022. doi:10.1002/ctd2.100
BibTeX
@article{Marimuthu2022,
author = {Marimuthu, Saravanakumar and Batra, Surinder K and Ponnusamy, Moorthy P},
title = {Pan‐cancer analysis of altered glycosyltransferases confers poor clinical outcomes},
journal = {Clinical and Translational Discovery},
year = {2022},
doi = {10.1002/ctd2.100}
}
EUVIMED